Science Explorer Back to mapMap
Discussion
Topic · Public Health, Environmental and Occupational Health

Gestational Trophoblastic Disease Studies

Gestational Trophoblastic Disease Studies is a research topic within Public Health, Environmental and Occupational Health. Science Explorer counts 11k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the diagnosis, management, and genetic aspects of gestational trophoblastic disease, including hydatidiform mole, choriocarcinoma, and placental site trophoblastic tumor. It covers topics such as epidemiology, pathology, clinical presentation, treatment outcomes, and molecular genetics of these conditions.

  • Gestational Trophoblastic Disease
  • Hydatidiform Mole
  • Choriocarcinoma
  • Trophoblastic Tumor
  • Molar Pregnancy
  • Placental Site Trophoblastic Tumor
  • Genetic and Epigenetic Analysis
  • Chemotherapy
  • Immunohistochemistry
  • Prenatal Diagnosis
Research works
11k
fractional, since 1950
In the world top 10%
1.2k
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+13%
the tick is no change
Largest producer
United States
28% of the 10 largest, 2022-now
Gestational Trophoblastic Disease Studies

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Gestational Trophoblastic Disease Studies research?

By volume, the United States and China publish the most (354 and 281 works in 2022-now).

By volume, 2022-now

  1. 1 United States 354 works
  2. 2 China 281 works
  3. 3 India 198 works
  4. 4 Japan 96 works
  5. 5 United Kingdom 74 works
  6. 6 Brazil 54 works
  7. 7 Iran 49 works
  8. 8 Türkiye 49 works
  9. 9 Indonesia 46 works
  10. 10 Italy 43 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 28.5%China: 22.6%India: 15.9%Japan: 7.7%6 others listed: 25.3%28%largest
United States354 · 28.5%China281 · 22.6%India198 · 15.9%Japan96 · 7.7%6 others listed314 · 25.3%

Shares of the rows listed above, not of the whole node.

Which institutions lead Gestational Trophoblastic Disease Studies research?

By volume in 2022-now, All India Institute of Medical Sciences publishes the most Gestational Trophoblastic Disease Studies research, followed by Zhejiang University and Harvard University.

By volume, 2022-now

  1. 1 All India Institute of Medical SciencesIndia 23 works
  2. 2 Zhejiang UniversityChina 19 works
  3. 3 Harvard UniversityUnited States 15 works
  4. 4 Sichuan UniversityChina 13 works
  5. 5 Yale UniversityUnited States 12 works
  6. 6 Tehran University of Medical SciencesIran 11 works
  7. 7 Tsinghua UniversityChina 9 works
  8. 8 Padjadjaran UniversityIndonesia 9 works
  9. 9 Centre Hospitalier Universitaire Hassan IIMorocco 9 works
  10. 10 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 9 works

Who are the leading researchers in Gestational Trophoblastic Disease Studies?

The most-cited researchers publishing on Gestational Trophoblastic Disease Studies include Hagop M. Kantarjian, Patrick M. Bossuyt and Carlo La Vecchia.

  1. 1 Hagop M. Kantarjian United States 273k citations
  2. 2 Patrick M. Bossuyt Netherlands 270k citations
  3. 3 Carlo La Vecchia Italy 258k citations
  4. 4 Elisabete Weiderpass France 221k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Gestational Trophoblastic Disease Studies?

The most cited paper in Gestational Trophoblastic Disease Studies is "Role for DNA methylation in genomic imprinting" (En Li, Caroline Beard, Rudolf Jaenisch, 1993), with 1,974 citations. Next come "Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement" (1,771) and "Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study" (1,410).

Most cited papers
#PaperReleasedCitations
1 Role for DNA methylation in genomic imprinting En Li, Caroline Beard, Rudolf Jaenisch · Nature Dec 1993 1,974
2 Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement Teck Yee Khong et al. · Archives of Pathology & Laboratory Medicine Open access 25 May 2016 1,771
3 Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study Louise Arseneault, Mary D Cannon, Richie Poulton et al. · BMJ Open access 21 Nov 2002 1,410
4 First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome Fergal Desmond Malone, Jacob A. Canick, Robert Hamilton Ball et al. · New England Journal of Medicine Open access 9 Nov 2005 1,084
5 Gestational trophoblastic disease Michael J. Seckl, Neil James Sebire, Ross Stuart Berkowitz · The Lancet 30 Jul 2010 1,048
All 98 most cited papers, with filters and sorting

Where is Gestational Trophoblastic Disease Studies research done?

The largest centres of Gestational Trophoblastic Disease Studies research in 2022-now are Beijing (China), Hangzhou (China), London (United Kingdom) and New Delhi (India).

Largest cities, 2022-now

  1. 1 BeijingChina 33 works
  2. 2 HangzhouChina 31 works
  3. 3 LondonUnited Kingdom 26 works
  4. 4 New DelhiIndia 24 works
  5. 5 TehranIran 21 works
  6. 6 ShanghaiChina 19 works
  7. 7 ChengduChina 18 works
  8. 8 GuangzhouChina 18 works
  9. 9 TokyoJapan 18 works
  10. 10 HoustonUnited States 17 works
See Gestational Trophoblastic Disease Studies on the map

Where is the best place to study Gestational Trophoblastic Disease Studies?

Among universities, judged by research, Harvard University, Yale University and Zhejiang University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 13.66%fractional works in this field (log) →share of work in the world top 10% →Harvard UniversityYale UniversityZhejiang UniversityAll India Institute …
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 68.823.2%2.8×15 -24.6%
2Yale UniversityUnited States 62.320.3%6.3×12 +84.7%
3Zhejiang UniversityChina 60.116.6%4.2×19 +1.9%
4All India Institute of Medical SciencesIndia 58.07.3%12.1×22 +171.0%
5University of California, San FranciscoUnited States 54.419.8%7.1×9 +93.2%
6Tehran University of Medical SciencesIran 38.86.1%10.9×11 +87.4%
7Sichuan UniversityChina 35.86.1%3.3×13 +16.6%
8Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 35.617.2%5.0×9 -4.7%
9Tsinghua UniversityChina 32.615.0%2.4×10 +0.5%
10Nagoya UniversityJapan 32.05.0%10.5×9 +137.6%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Gestational Trophoblastic Disease Studies, country by country

Is Gestational Trophoblastic Disease Studies research growing?

Output in 2022-2025 was 13% higher than in 2018-2021, peaking in 2021. The fastest-growing topics are Gestational Trophoblastic Disease Studies.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Gestational Trophoblastic Disease Studies as a percentage of every work published that year, 0.0081% in 2024.

still counting0.010%0.020%0.030%Gestational Trophoblastic Disease Studies0.0076% in 202519801990200020102020

Fractional works of Gestational Trophoblastic Disease Studies over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Gestational Trophoblastic Disease Studies10.6% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Gestational Trophoblastic Disease Studies. Posts are plain text and can be reported.